N/A
Manufactured by Cipla USA Inc.
25,519 FDA adverse event reports analyzed
Last updated: 2026-04-14
RITONAVIR 100 MG is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Cipla USA Inc.. The most commonly reported adverse reactions for RITONAVIR 100 MG include DRUG INTERACTION, FOETAL EXPOSURE DURING PREGNANCY, MATERNAL EXPOSURE DURING PREGNANCY, VIROLOGIC FAILURE, EXPOSURE DURING PREGNANCY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RITONAVIR 100 MG.
Out of 14,764 classified reports for RITONAVIR 100 MG:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 25,519 FDA FAERS reports that mention RITONAVIR 100 MG. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INTERACTION, FOETAL EXPOSURE DURING PREGNANCY, MATERNAL EXPOSURE DURING PREGNANCY, VIROLOGIC FAILURE, EXPOSURE DURING PREGNANCY, DRUG RESISTANCE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Cipla USA Inc. in connection with RITONAVIR 100 MG. Always verify the specific product and NDC with your pharmacist.